Novel pharmacotherapies in diabetic retinopathy

Middle East African Journal of Ophthalmology

Volumn 22, Issue 2, 2015, Pages 164-173

  Dedania, Vaidehi S ^a   Bakri, Sophie J ^b  

^a ALBANY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Corticosteroids; Diabetic retinopathy; Eye; Intravitreal Injection; Treatment; Vascular endothelial growth factor

Indexed keywords

AGENTS ACTING ON THE EYE; ALDEHYDE REDUCTASE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FLUOCINOLONE ACETONIDE; PROTEIN KINASE C; PROTEIN KINASE C BETA INHIBITOR; RANIBIZUMAB; SIGNAL TRANSDUCTION PATHWAY INHIBITOR; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG THERAPY; EYE INFLAMMATION; HUMAN; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VITREORETINOPATHY; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; MACULAR EDEMA; MULTIMODALITY CANCER THERAPY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

EID: 84926619597     PISSN: 09749233     EISSN: 09751599     Source Type: Journal    
DOI: 10.4103/0974-9233.154389     Document Type: Review

References (86)

1. Ruigómez A, García Rodríguez LA. Presence of diabetes related complication at the time of NIDDM diagnosis: An important prognostic factor. Eur J Epidemiol 1998;14:439-45.
2. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1-9.
3. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995;113:36-51.
4. The Diabetes Control and Complications Trial. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-9.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
6. The United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J 1998;317:703-13.
7. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings, DRS Report Number 8. Ophthalmology 1981;88:583-600.
8. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98 5 Suppl: 766-85.
9. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treat-ment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
10. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987;27:254-64.
11. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
12. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48.
13. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
14. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS, Macugen 1013 Study Group. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118:1107-18.
15. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab versus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Diabetic Retinopathy Clinical Research Network. Ophthalmology 2010;117:1064-77.
16. Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 2009;127:132-40.
17. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
18. Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: The RESTORE extension study. Ophthalmology 2014;121:1045-53.
19. Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, Xing W, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol 2014;157:960-70.
20. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology 2010;117:1078-86.e2.
21. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014;121:2247-54.
22. Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, et al. The DA VINCI Study: Phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819-26.
23. Huang J, Li X, Li M, Li S, Xiao W, Chen X, et al. Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab 2012;14:644-53.
24. Blumenkranz M. Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual Acuity. 40th Annual Meeting of the Retina Society, Boston, MA; September 27-30, 2007.
25. Yang Y, Yang K, Li Y, Li X, Sun Q, Meng H, et al. Decursin inhibited proliferation and angiogenesis of endothelial cells to suppress diabetic retinopathy via VEGFR2. Mol Cell Endocrinol 2013;378:46-52.
26. Shen J, Yang X, Xiao WH, Hackett SF, Sato Y, Campochiaro PA. Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J 2006;20:723-5.
27. Prenner JL. RACE Study Group. The RACE Study: Bevasiranib for the treatment of diabetic macular edema (abstract 5045). Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL; October 5, 2007.
28. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999;285:245-8.
29. Gao G, Li Y, Fant J, Crosson CE, Becerra SP, Ma Jx. Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium - derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes 2002;51:1218-25.
30. Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, Yu WZ, et al. Polyethylene glycol-modified pigment epithelial-derived factor: New prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther 2012;342:131-9.
31. Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ, Tombran-Tink J. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Mol Med 2012;18:1387-401.
32. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study. Diabetes Care 2000;23:504-9.
33. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001;33:300-6.
34. Kuijpers RW, Baarsma S, van Hagen PM. Treatment of cystoid macular edema with octreotide. N Engl J Med 1998;338:624-6.
35. Hernández C, Simó R, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Somatostatin replacement: A new strategy for treating diabetic retinopathy. Curr Med Chem 2013;20:3251-7.
36. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. the effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001;108:2266-72.
37. A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00414999. [Last accessed on 2014 Sep 17].
38. Thakur A, Scheinman RI, Rao VR, Kompella UB. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res 2011;82:346-50.
39. Cohen MP, Hud E, Wu VY, Shearman CW. Amelioration of diabetes-associated abnormalities in the vitreous fluid by an inhibitor of albumin glycation. Invest Ophthalmol Vis Sci 2008;49:5089-93.
40. Cohen MP, Lautenslager GT, Hud E, Shea E, Wang A, Chen S, et al. Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency. Am J Physiol Renal Physiol 2007;292:F789-95.
41. Miyamoto N, Iossifov D, Metge F, Behar-Cohen F. Early effects of intravitreal triamcinolone on macular edema: Mechanistic implication. Ophthalmology 2006;113:2048-53.
42. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51.
43. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-14.
44. Nakano Goto S, Yamamoto T, Kirii E, Abe S, Yamashita H. Treatment of diffuse diabetic macular oedema using steroid eye drops. Acta Ophthalmol 2012;90:628-32.
45. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32.
46. Schoenberger SD, Kim SJ, Shah R, Sheng J, Cherney E. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. JAMA Ophthalmol 2014;132:32-7.
47. Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Retina 2010;30:459-67.
48. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007;56:373-9.
49. Yang LP, Sun HL, Wu LM, Guo XJ, Dou HL, Tso MO, et al. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci 2009;50:2319-27.
50. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, Anastasakis A, Krikonis TS, Christodoulakis E. The use of intravitreal etanercept in diabetic macular oedema. Semin Ophthalmol 2007;22:75-9.
51. Sfikakis PP, Markomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005;28:445-7.
52. Cellini M, Balducci N, Strobbe E, Campos EC. Subtenon injection of natural leukocyte interferon á-2a in diabetic macular edema: A case report. BMC Ophthalmol 2013;13:63.
53. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473-80.
54. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-31.
55. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171-9.
56. Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, et al. Oral protein kinase c Beta inhibition using ruboxistaurin: efficacy, safety and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C Beta Inhibitor- Diabetic Retinopathy Study and the Protein Kinase C Beta Inhibitor-Diabetic Retinopathy Study 2. Retina 2011;31:2084-94.
57. Seo MS, Kwak N, Ozaki H, Yamada H, Okamoto N, Yamada E, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 1999;154:1743-53.
58. Abiko T, Abiko A, Clermont AC, Shoelson B, Horio N, Takahashi J, et al. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: Role of oxidants and protein kinase-C activation. Diabetes 2003;52:829-37.
59. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006;55:2757-62.
60. Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB, et al. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int J Mol Med 2008;21:667-76.
61. Hattori T, Matsubara A, Taniguchi K, Ogura Y. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo. Curr Eye Res 2010;35:146-54.
62. Zheng L, Kern TS. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front Biosci (Landmark Ed) 2009;14:3974-87.
63. Mohammad G, Siddiquei MM, Abu El-Asrar AM. Poly (ADP-ribose) polymerase mediates diabetes-induced retinal neuropathy. Mediators Inflamm 2013;2013:510451.
64. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, et al. (Pro) renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 2009;58:1625-33.
65. Zhang X, Lassila M, Cooper ME, Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 2004;43:276-81.
66. Mohamed Q, Wong TY. Emerging drugs for diabetic retinopathy. Expert Opin Emerg Drugs 2008;13:675-94.
67. Ahmadieh H, Nourinia R, Hafezi-Moghadam A. Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: A novel treatment. JAMA Ophthalmol 2013;131:923-4.
68. Lee K, Hu Y, Ding L, Chen Y, Takahashi Y, Mott R, et al. Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes 2012;61:2948-57.
69. Hu B, Zhang Y, Zeng Q, Han Q, Zhang L, Liu M, et al. Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes. Int J Mol Sci 2014;15:1606-24.
70. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 2012;53:7666-74.
71. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, et al. The role of the vitreous in diabetic macular edema. Ophthalmology 1988;95:1335-9.
72. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR, Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:585-97.
73. Xu H, Zhang L, Gu L, Lu L, Gao G, Li W, et al. Subretinal delivery of AAV2-mediated human erythropoietin gene is protective and safe in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci 2014;55:1519-30.
74. Rosales MA, Silva KC, Duarte DA, de Oliveira MG, de Souza GF, Catharino RR, et al. S-nitrosoglutathione inhibits inducible nitric oxide synthase upregulation by redox posttranslational modification in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci 2014;55:2921-32.
75. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 2007;48:858-65.
76. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: Aminoguanidine and aspirin. Diabetes 2001;50:1636-42.
77. Bhatwadekar A, Glenn JV, Figarola JL, Scott S, Gardiner TA, Rahbar S, et al. A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol 2008;92:545-7.
78. Steigerwalt R, Nebbioso M, Appendino G, Belcaro G, Ciammaichella G, Cornelli U, et al. Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Med 2012;54:11-6.
79. Gillies MC, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, et al. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology 2011;118:866-72.
80. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-51.
81. Nishimura M, Nakano K, Ushiyama M, Nanbu A, Ohtsuka K, Takahashi H, et al. Increased serum concentrations of human hepatocyte growth factor in proliferative diabetic retinopathy. J Clin Endocrinol Metab 1998;83:195-8.
82. Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2001;21:28-33.
83. Capeans C, De Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998;18:546-50.
84. Feener EP. Plasma kallikrein and diabetic macular edema. Curr Diab Rep 2010;10:270-5.
85. Rangasamy S, Srinivasan R, Maestas J, McGuire P, Das A. A potential role of angiopoietin-2 in the alteration of the blood-retinalbarrier in diabetic retinopathy. Invest Ophthalmol Vis Sci 2011;52:3784-91.
86. Yoshida A, Yoshida S, Ishibashi T, Kuwano M, Inomata H. Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice. Invest Ophthalmol Vis Sci 1999;40:1624-9.